GT Biopharma (GTBP) had the highest return in 2017 and in March 2017 by a US stock, returning 5,888,081.8%.
| ASSET | % RETURN |
|---|---|
GT Biopharma (GTBP) | 5,888,081.82% |
OLB (OLB) | 200% |
Lixte Biotechnology (LIXT) | 177.78% |
Fubotv (FUBO) | 161.32% |
TSS, Inc Common Stock (TSSI) | 118.99% |
LifeMD (LFMD) | 108.33% |
TG Therapeutics (TGTX) | 104.39% |
Aurinia Pharmaceuticals (AUPH) | 102.2% |
Opus Genetics (IRD) | 101.98% |
Sobr Safe (SOBR) | 87.5% |
Castellum (CTM) | 83.64% |
Power Solutions International, Inc Common Stock (PSIX) | 83.45% |
Verastem (VSTM) | 80% |
Clearpoint Neuro (CLPT) | 79.86% |
GrabAGun Digital (PEW) | 76.92% |
Catalyst Pharmaceuticals (CPRX) | 75.68% |
Nektar Therapeutics (NKTR) | 75.67% |
Harrow Health (HROW) | 72.31% |
Akari Therapeutics (AKTX) | 66.72% |
Oncolytics Biotech (ONCY) | 61.25% |
Cassava Sciences (SAVA) | 56.14% |
Eterna Therapeutics (ERNA) | 55.8% |
VerifyMe (VRME) | 54.84% |
Quipt Home Medical (QIPT) | 53.54% |
HUTCHMED DRC (HCM) | 53.46% |
